Tag: Nectero Medical
Nectero Medical announces completion of US$96 million Series D financing
Nectero Medical recently announced the closing of its US$96 million Series D financing round.
Financing was led by Norwest Venture Partners, with large investments...
Vascular News’ top 10 most popular stories of January 2024
January's top 10 highlights new guidelines from the European Society for Vascular Surgery (ESVS), an expert consensus roundtable on the benefits of intravascular ultrasound...
Nectero Medical announces initiation of Phase II/III clinical trial of the...
Nectero Medical today announced initiation of a Phase II/III clinical trial (stAAAble) to investigate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilisation...
Nectero Medical granted Breakthrough Therapy designation for the Nectero EAST system...
Nectero Medical today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilisation Treatment...
Alcami supports Phase II/III trial supply of the Nectero EAST system
Alcami has welcomed the recent announcement by Nectero Medical that it has received clearance from the US Food and Drug Administration (FDA) of their...
Nectero EAST® System touted as potential “game changer” for smaller infrarenal...
“A truly novel and potentially groundbreaking treatment strategy for patients with small to mid-sized infrarenal abdominal aortic aneurysms,” is how Michael R. Jaff (Boston,...
Vascular News’ top 10 most popular stories of July 2023
July's top 10 highlights the US Food and Drug Administration's long-awaited update on paclitaxel-coated devices to treat peripheral arterial disease, an interview with Rachel...
Nectero Medical receives FDA clearance of IND application to initiate Phase...
Nectero Medical today announced that the US Food and Drug Administration (FDA) has granted investigational new drug (IND) clearance for the company to initiate...
